Targeting the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway with JAK inhibitors could lead to significant repigmentation in patients with vitiligo [4, 5]. This evidence concerns the gene SOAT1 and vitiligo.